Cannabinoid Therapeutics in Parkinson's Disease: Promise and Paradox
Parkinson's disease (PD) involves neuroinflammation, excitotoxicity, mitochondrial dysfunction, and diminished trophic support. The endo-cannabinoid system (comprising small bioactive compounds, their synthetic and catabolic enzymes, their metabotropic and ionotropic receptors, and their transporters) has been implicated in neurophysiology and neurodegeneration, leading to the proposal of medicines derived from Cannabis sativa as new PD therapies. Here, the potential for cannabinoid-based PD therapies is reviewed. The clinical significance of cannabinoids in PD presents both promise and paradox, with varied data emerging from disparate model systems, clinical trials, and delivery modalities, including medical applications of native (plant-derived) and synthetic cannabis products. This picture is complicated further by the multivariate involvement of metabotropic and ionotropic receptors, an emerging understanding of new cannabinoid targets (e.g., PPARγ and GPRs18, 55, and 119), and the potential role of entourage compounds (e.g., geraniol, apigenin) in any protective or therapeutic effects observed..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of herbs, spices & medicinal plants - 23(2017), 3, Seite 231 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Turner, Helen [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1080/10496475.2017.1312724 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1995227404 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995227404 | ||
| 003 | DE-627 | ||
| 005 | 20230513153246.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10496475.2017.1312724 |2 doi | |
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1995227404 | ||
| 035 | |a (DE-599)GBVOLC1995227404 | ||
| 035 | |a (PRQ)i1131-b8ac820f0cdcb0a899bc2a8407e331eade07727bd36d652469d1d02443f473d00 | ||
| 035 | |a (KEY)0211986220170000023000300231cannabinoidtherapeuticsinparkinsonsdiseasepromisea | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 580 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 42.38 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Turner, Helen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoid Therapeutics in Parkinson's Disease: Promise and Paradox |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Parkinson's disease (PD) involves neuroinflammation, excitotoxicity, mitochondrial dysfunction, and diminished trophic support. The endo-cannabinoid system (comprising small bioactive compounds, their synthetic and catabolic enzymes, their metabotropic and ionotropic receptors, and their transporters) has been implicated in neurophysiology and neurodegeneration, leading to the proposal of medicines derived from Cannabis sativa as new PD therapies. Here, the potential for cannabinoid-based PD therapies is reviewed. The clinical significance of cannabinoids in PD presents both promise and paradox, with varied data emerging from disparate model systems, clinical trials, and delivery modalities, including medical applications of native (plant-derived) and synthetic cannabis products. This picture is complicated further by the multivariate involvement of metabotropic and ionotropic receptors, an emerging understanding of new cannabinoid targets (e.g., PPARγ and GPRs18, 55, and 119), and the potential role of entourage compounds (e.g., geraniol, apigenin) in any protective or therapeutic effects observed. | ||
| 540 | |a Nutzungsrecht: Published with license by Taylor & Francis. © 2017 Helen Turner, Daniel Chueh, Tony Ortiz, Alexander J. Stokes, and Andrea L. Small-Howard. | ||
| 650 | 4 | |a Cannabis | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a marijuana | |
| 650 | 4 | |a Parkinsons disease | |
| 700 | 1 | |a Chueh, Daniel |4 oth | |
| 700 | 1 | |a Ortiz, Tony |4 oth | |
| 700 | 1 | |a Stokes, Alexander J |4 oth | |
| 700 | 1 | |a Small-Howard, Andrea L |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of herbs, spices & medicinal plants |d Binghamton, NY : Food Products Pr., 1992 |g 23(2017), 3, Seite 231 |w (DE-627)131118757 |w (DE-600)1122804-0 |w (DE-576)490051995 |x 1049-6475 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:3 |g pages:231 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1080/10496475.2017.1312724 |3 Volltext |
| 856 | 4 | 2 | |u http://www.tandfonline.com/doi/abs/10.1080/10496475.2017.1312724 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1900934931 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 42.38 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 3 |h 231 | ||